129 Xenon Imaging in Patients Treated With Sotatercept

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

August 1, 2026

Study Completion Date

August 1, 2026

Conditions

Pulmonary HypertensionPulmonary Arterial Hypertension

Interventions

DRUG

129Xe Hyperpolarized

Each xenon dose will be limited to a volume less than 25% of participant lung capacity (TLC).

Trial Locations (1)

Duke University Medical Center, Durham

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Bastiaan Driehuys

OTHER